Kyongbo Pharmaceutical Co., Ltd (KRX:214390)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,100.00
-50.00 (-0.97%)
At close: Jul 24, 2025, 3:30 PM KST
-0.97%
Market Cap122.88B
Revenue (ttm)236.54B
Net Income (ttm)2.29B
Shares Out23.91M
EPS (ttm)95.99
PE Ratio53.55
Forward PEn/a
Dividend50.00 (0.97%)
Ex-Dividend DateDec 27, 2024
Volume20,572
Average Volume20,741
Open5,150.00
Previous Close5,150.00
Day's Range5,095.00 - 5,180.00
52-Week Range4,755.00 - 7,500.00
Beta1.15
RSI52.35
Earnings DateAug 14, 2025

About Kyongbo Pharmaceutical

Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagnostic equipment; and extraporeal shockwave therapy and temperature control PROBE. In addition, the company is involved in CDMO business; and research an... [Read more]

Sector Healthcare
Founded 1987
Country South Korea
Stock Exchange Korea Stock Exchange
Ticker Symbol 214390
Full Company Profile

Financial Performance

In 2024, Kyongbo Pharmaceutical's revenue was 238.56 billion, an increase of 10.26% compared to the previous year's 216.36 billion. Earnings were 4.64 billion, an increase of 55.98%.

Financial Statements

News

There is no news available yet.